Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice

Early Intervention in Psychiatry
Bunta YoshimuraNorihito Yamada

Abstract

Little is known about the clinical outcomes of severely ill patients with first-episode schizophrenia spectrum disorders (FES) who are considered to lack the capacity to consent to clinical trials. We investigated the feasibility of an algorithm-based pharmacotherapy (ABP) and clinical outcomes of patients with FES involuntarily hospitalized and treated with ABP. We conducted a retrospective chart review of 160 patients admitted involuntarily between October 2012 and October 2015. Our algorithm aimed to delay olanzapine, standardize medications and suggest initiation of clozapine after failure (non-response or intolerability) of third-line antipsychotic treatment. The duration of each adequate antipsychotic treatment at optimal dosage was 4 weeks or more. The physician adherence rate to ABP was 95%. Response and remission rates were 76.0% and 48.6% in the first adequate antipsychotic trial (Phase I, n = 146), 62.5% and 25.0% in the second adequate antipsychotic trial (Phase II, n = 32), and 16.7% and 0% in the third adequate antipsychotic trial (Phase III, n = 6). Response and remission rates in the clozapine trial (n = 9) increased to nearly the level of Phase I (66.7% and 44.4%). The treatment-resistance rate was 8.4% to 10.3...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·S H JonesG Dunn
Jul 6, 2004·Journal of Critical Care·Tasnim SinuffUNKNOWN Department of Medicine, McMaster University
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Nov 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Robert E McCueSyed M Hasan
Nov 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Craig MorganUNKNOWN AESOP Study Group
Dec 5, 2006·CNS Drugs·Tracy Swainston Harrison, Lesley J Scott
Jun 26, 2009·Schizophrenia Research·Kotaro HattaYutaka Sawa
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Jun 4, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jimmi NielsenChristoph U Correll
Sep 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shin OginoNoboru Yamaguchi
Jan 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rebecca Schennach-WolffMichael Riedel
Feb 9, 2011·Archives of General Psychiatry·Debra L Foley, Katherine I Morley
Sep 24, 2011·The Journal of Clinical Psychiatry·Juan A GallegoJohn M Kane
Nov 30, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Rei KitajimaNoboru Yamaguchi
Dec 25, 2012·CNS Drugs·Mark Sanford
May 10, 2013·Harvard Review of Psychiatry·David N OsserTheo Manschreck
Nov 1, 2013·World Journal of Psychiatry·Francisco Javier AcostaCarlos J Rodríguez
Jan 5, 2014·The Cochrane Database of Systematic Reviews·Priya KhannaJun Xia
Mar 29, 2014·Current Medical Research and Opinion·Leslie CitromeTony Hebden
Jul 15, 2015·International Clinical Psychopharmacology·Alp ÜçokRümeysa Durak
Aug 10, 2015·Schizophrenia Research·Yuji YadaYoshiki Kishi
Jun 17, 2016·Journal of Clinical Psychopharmacology·Saínza GarcíaAna González-Pinto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Actin-binding Proteins

Actin-binding proteins are a component of the actin cytoskeleton that play essential roles in cellular functions such as regulation of actin polymerization, maintenance of cell polarity, gene expression regulation, cell motility and many more functions. Discover the latest research on actin-binding proteins here.

Related Papers

The American Journal of Psychiatry
Theodore T KolivakisGuy Chouinard
The British Journal of Psychiatry : the Journal of Mental Science
Myrto Samara, Stefan Leucht
American Journal of Therapeutics
Peter Manu, Eugene Grudnikoff
© 2022 Meta ULC. All rights reserved